Abstract CT078: Phase 1 study of SGN-EGFRd2 in solid tumors (SGNEGFRd2-001)
Hirva Mamdani(Wayne State University), David L. Bajor(University Hospitals of Cleveland), Mingjin Yan(Seagen (United States)), Rachel E. Sanborn(Providence Portland Medical Center), J. Randolph Hecht(Ontario Institute for Cancer Research), Martin Gutierrez(Hackensack University Medical Center), Maria Corinna Palanca-Wessels(Unknown)
Cited by 3
Related Papers
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|846